Skip to main
CADL
CADL logo

Candel Therapeutics (CADL) Stock Forecast & Price Target

Candel Therapeutics (CADL) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Candel Therapeutics Inc has reported an increase in median overall survival for CAN-2409, rising from 28.8 months in the April 2024 data cut, which bolsters confidence in its efficacy and potential marketability. Furthermore, the company has enhanced its probability of FDA approval, raising expectations for CAN-2409 in prostate cancer to 45% and in pancreatic cancer to 40%, indicating strong supportive data for its mechanisms of action. The promising results from CAN-2409’s Phase 1b clinical trial, which showed a significant increase in CD8+ tumor infiltration lymphocytes, further underscore the drug's potential to translate into positive outcomes across various indications, notably in the upcoming trials for non-small cell lung cancer.

Bears say

Candel Therapeutics faces substantial risks related to the efficacy of its clinical trials for CAN-2409 and CAN-3110, which may not meet expectations compared to other treatments for the same indications. The company reported a significant net loss of $14.1 million in 4Q24, indicating ongoing financial challenges that could necessitate capital raises under unfavorable conditions, leading to potentially excessive shareholder dilution. Additionally, uncertainties surrounding regulatory requirements, unproven commercialization strategies, and the competitive landscape further compound the negative outlook for Candel's stock performance.

Candel Therapeutics (CADL) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Candel Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Candel Therapeutics (CADL) Forecast

Analysts have given Candel Therapeutics (CADL) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Candel Therapeutics (CADL) has a Strong Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Candel Therapeutics (CADL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.